QBiotics Announces First Patient Dosed in its Phase I/II Clini...
BRISBANE, Australia, Dec. 3, 2019 /PRNewswire-AsiaNet/ -- - First patient successfully dosed in QBiotics' Phase I/II clinical trial of tigilanol tiglate in patients with Head and Neck Squamous Cell Carcinoma (HNSCC) - Tigilanol tiglate is a novel, small molecule that is being tested as a single injecti...
Authors: LATEST ASIANET NEWS RELEASES